| Issue | Title | |
| Vol 2013, No 6 (2013) | Valeant Aims to Compete in Ophthalmology with US$8.7 B Bausch & Lomb Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 7 (2011) | Valeant Continues its Acquisition Spree with Agreement to Buy Janssen’s Ortho Dermatologics Division | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 6 (2011) | Valeant Continues its Expansion in Central and Eastern Europe with Sanitas Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 10 (2012) | Valeant Expands in Ophthalmology with Acquisition of QLT’s Visudyne ® | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 57 (2005) | Valeant Expands Neurology Franchise through Acquisition of Xcel | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 4 (2012) | Valeant Further Expands in Russia with Natur Produkt Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2013, No 4 (2013) | Valeant Increases Offer for Obagi Medical Products After Merz Pharma Bid | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 99 (2008) | Valeant Licenses Epilepsy Drug to GSK | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2015, No 9 (2015) | Valeant Licenses Rights to AstraZeneca’s Troubled Psoriasis Drug Brodalumab | Abstract html html |
| Heather Cartwright & Shruti Desai | ||
| Vol 2011, No 9 (2011) | Valeant Outbids Paladin Labs with US$78 M Offer to Acquire Afexa Life Sciences | Abstract |
| Hetather Cartwright | ||
| Vol 2010, No 5 (2010) | Valeant Pharma acquires Aton Pharma for USD 318 M | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 99 (2008) | Valeant Pharmaceuticals’ De-Globalisation Strategy Sees the Sale of European Operations | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2015, No 3 (2015) | Valeant Settles for Second Best with US$14.5 B Salix Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 2 (2011) | Valeant to Acquire PharmaSwiss and Expand its Presence in Central and Eastern Europe | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 7 (2011) | Valeant to Buy Sanofi’s Dermik Skincare Unit for US$425 M | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 9 (2012) | Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 80 (2007) | Validation and Value: The Risk of RNAi Therapeutics | Abstract |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | Valtaxin (valrubicin) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 82 (2007) | Valuation Methodologies in Biotech | Abstract pdf |
| Business Review Editor | ||
| Vol 2017, No 12 (2017) | Value for Money? An Analysis of Five Product-Driven M&A Deals | Abstract pdf |
| Heather Cartwright & Dan Roberts | ||
| Vol 2012, No 9 (2012) | Vascular Pharma Completes US$16 M Series A Financing and Grants Janssen Biotech Acquisition Option | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 81 (2007) | VASTox Signs Drug Discovery Deals Worth a Combined US$1.3 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | VaxGen Amends Agreement with Genentech for AIDSVAX | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | Vectibix (panitumumab) | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 4 (2016) | Vectura Acquires SkyePharma for US$628 M to Lead in Inhalation Devices | Abstract pdf html |
| Heather Cartwright & Rohit Khera | ||
| Vol 2013, No 5 (2013) | Vectura Forays into China by Forming JV with Tianjin KingYork and Zendex Bio Strategy | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 61 (2005) | Vectura Group plc | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 79 (2007) | Vectura to Take Over Innovata | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 3 (2014) | Vectura Ventures into Nebuliser Market with Activaero Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 34 (2003) | Vencor to Distribute Efoora’s Rapid HIV Test Worldwide | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | Venture Capitalist | Details jpg |
| Business Review Editor | ||
| Vol 2008, No 91 (2008) | Vernakalant | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 25 (2002) | Vernalis & Roche enter new collaboration in depression and anxiety | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 50 (2004) | Vernalis Licenses its Lead Compound for Parkinson’s disease to Biogen Idec | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 8 (2009) | Vernalis Rebounds on GSK Deal | Abstract |
| Taskin Ahmed | ||
| Vol 2002, No 27 (2002) | Versicor to Merge with Biosearch Italia | Abstract |
| Business Review Editor | ||
| Vol 2015, No 7 (2015) | Vertex Augments Cystic Fibrosis Pipeline with Parion Sciences Deal | Abstract html |
| Heather Cartwright & Hardik Mewada | ||
| Vol 2019, No 9 (2019) | Vertex Branches into Diabetes Field with Semma Therapeutics Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2024, No 4 (2024) | Vertex Buys Alpine Immune Sciences and its Kidney Disease Drug for US$4.9 B | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2022, No 7 (2022) | Vertex Buys ViaCyte for Diabetes Stem Cell Treatment | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2011, No 6 (2011) | Vertex Enhances its HCV Pipeline by Licensing Alios BioPharma’s Nucleotide Analogues | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 6 (2019) | Vertex Expands Gene Therapy Footprint with CRISPR Therapeutics and Exonics Deals | Abstract pdf html |
| Michelle Liu | ||
| Vol 2019, No 5 (2019) | Vertex Joins Protein Degradation Space with Kymera Therapeutics Collaboration | Abstract pdf html |
| Michelle Liu | ||
| Vol 2005, No 58 (2005) | Vertex Opts for Avalon to Progress VX-944 | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 11 (2012) | Vertex Partners with GSK and Janssen on Phase II Studies of All-Oral HCV Treatment Regimens | Abstract |
| Heather Cartwright | ||
| Vol 2017, No 3 (2017) | Vertex Protects Cystic Fibrosis Franchise by Acquiring CTP-656 from Concert | Abstract pdf html |
| Natasha Piper | ||
| Vol 2022, No 7 (2022) | Vertex Signs Gene Editing Partnership with Verve for US$466 M | Abstract pdf html |
| Swati Sharan | ||
| Vol 2024, No 7 (2024) | Vertex Signs License Agreement with Orum Therapeutics to Develop Novel Degrader-Antibody Conjugates for Conditioning Agents | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2020, No 5 (2020) | Vertex Signs US$1.6 B Gene Therapy Vector Partnership with Affinia | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 74 (2006) | Vertex Views Success on the Horizon | Abstract |
| Business Review Editor | ||
| Vol 2004, No 50 (2004) | Vertex: An Accomplished Dealmaker | Abstract |
| Business Review Editor | ||
| Vol 2006, No 73 (2006) | Vical and AnGes Collaborate on Late-Stage Cancer Therapy. | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 64 (2005) | Vical Grants More Options to Merck & Co. for Cancer Targets | Abstract pdf |
| Business Review Editor | ||
| Vol 2021, No 12 (2021) | Vifor Enters Two Multimillion-Dollar Deals to Expand Nephrology Portfolio | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2007, No 90 (2007) | Vioxx®: A Painful Lesson | Abstract |
| Business Review Editor | ||
| Vol 2007, No 81 (2007) | Viral Gene Delivery #8211; Gene Therapy and Beyond | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 11 (2011) | ViroPharma to Broaden its Orphan Drug Portfolio with DuoCort Pharma Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 10 (2011) | ViroPharma to Develop Intellect Neurosciences’ OX1 for Friedreich’s Ataxia | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 86 (2007) | Viviant (bazedoxifene) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 82 (2007) | Vyvanse (lisdexamfetamine dimesylate) | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 6 (2009) | Watson Acquires Arrow in Bid for International Expansion | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 6 (2011) | Watson Increases its European Presence with US$563 M Specifar Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 48 (2004) | Watson Licenses North American Rights to Silodosin from Kissei | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | Watson Pharmaceuticals Enters Agreement for Novartis’ Headache Treatments | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 2 (2012) | Watson Strengthens its Presence in Australia and Southeast Asia with Acquisition of Strides Arcolab’s Ascent Pharmahealth | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 70 (2006) | Watson to Acquire Andrx for US$1.9 B | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 5 (2012) | Watson to Become World’s Third Largest Generics Company with US$5.9 B Actavis Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 10 (2011) | Whales | Abstract jpg |
| Clive Goddard | ||
| Vol 2007, No 81 (2007) | What's a good pipeline? | Abstract html |
| Fintan Walton | ||
| Vol 2006, No 68 (2006) | What's Special About Speciality? | Abstract html |
| Fintan Walton | ||
| Vol 2005, No 64 (2005) | When and How to Find the Right Partner | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 80 (2007) | When Giants Meet: Bristol-Myers Squibb and AstraZeneca Form Alliance for Diabetes Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 64 (2005) | Where Does Innovation Prosper? | Details html |
| Fintan Walton | ||
| Vol 2007, No 79 (2007) | Where Now for Biotech? | Abstract html |
| Fintan Walton | ||
| Vol 2007, No 76 (2007) | Who is Buying Who? | Abstract html |
| Fintan Walton | ||
| Vol 2009, No 2 (2009) | Who’s next for a mega merger? | Abstract html |
| Taskin Ahmed | ||
| Vol 2008, No 100 (2008) | Will Lehman’s Collapse Affect the Pharmaceutical Industry? | Abstract html |
| Fintan Walton | ||
| Vol 2006, No 77 (2006) | Winning – but at what Cost? | Abstract |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | Women First HealthCare Acquire Vaniqa from BMS | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 12 (2012) | Wright Medical Bets on BioMimetic Therapeutics with Merger Agreement | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 1 (2009) | Wyeth Acquisition Could be Major Distraction for Pfizer | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2007, No 82 (2007) | Wyeth Alters R&D to Address the Emerging Challenges Facing Biotech | Abstract |
| Business Review Editor | ||
| Vol 2006, No 78 (2006) | Wyeth and Ablynx Enter into Collaboration and Licence Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 47 (2004) | Wyeth and Solvay Form Neuroscience Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 1 (2009) | Wyeth Deals Signal Diversification Strategy | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2004, No 45 (2004) | Wyeth Licenses Hedgehog Technology for Nervous Disorders | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 27 (2002) | Wyeth Licenses Interleukin Receptor Patents from ZymoGenetics | Abstract |
| Business Review Editor | ||
| Vol 2006, No 67 (2006) | Wyeth Teams with NIAID on HIV/AIDS Vaccines | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 68 (2006) | Wyeth's Recognition of the Worth of Biotech | Abstract pdf |
| Business Review Editor | ||
| Vol 2019, No 2 (2019) | Xencor Collaborates with Genentech for Novel Interleukin-15 Bispecific Antibodies | Abstract pdf html |
| Jasmine Kalsi & Michelle Liu | ||
| Vol 2009, No 4 (2009) | Xencor Grants Merck Exclusive License for Xtend™ | Abstract |
| Taskin Ahmed | ||
| Vol 2012, No 2 (2012) | Xenon and Genentech Partner to Develop Pain Therapeutics and Companion Diagnostics | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 7 (2009) | Xenon and Merck Collaborate on Cardiovascular Disease Treatment | Abstract |
| Taskin Ahmed | ||
| Vol 2003, No 40 (2003) | Xenova Acquires KS Biomedix to Focus on Brain Cancer Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 24 (2002) | Xenova out-licenses preclinical technology to Genentech | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 53 (2004) | Xerion Pharmaceuticals AG | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | Xmas | Details jpg |
| Business Review Editor | ||
| Vol 2008, No 102 (2008) | XOMA Makes Cost-Cutting Move by Restructuring Novartis Deal | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2011, No 1 (2011) | Xoma Partners with Servier to Develop and Commercialise its Lead Anti-Inflammatory Drug | Abstract |
| Heather Cartwright | ||
| Vol 2023, No 6 (2023) | XtalPi Enters into Collaboration with Eli Lilly to Discover Drug Candidates Using Artificial Intelligence and Robotics Platform | Abstract pdf html |
| Ashish Tripathi | ||
| 2501 - 2600 of 2613 Items | << < 21 22 23 24 25 26 27 > >> | |